Study register · detail
Clear benefit
GRADE
Moderate
74 citations
Samplen = 29 Pat.
Durationup to 96 hours after dosing
ControlFasted state
EndpointAUC0-∞ and Cmax
Blindingoffen
DesignPhase-1-RCT (Pharmakokinetik + Sicherheit, gesunde Probanden)
Cannabinoidcbd
Max. dose750.0 mg
Routeoral
Key finding
High-fat meals increase CBD bioavailability the most (3,8-fold AUC, 5,2-fold Cmax), followed by low-fat meals, whole milk, and alcohol.
Summary
Phase 1 RCT (n=29 fasted reference group) on CBD 750 mg (Epidiolex) and the effect of food on exposure: AUC 3,8-fold higher with high-fat meal (vs. fasted), Cmax increased 5,2-fold; low-fat meal +2,7-fold AUC; whole milk +2,4-fold AUC; alcohol +1,6-fold AUC. No serious adverse events.
P
PopulationHealthy adults, n=29 (fasted), n=15 (high-fat/calorie meal), n=14 (low-fat/calorie meal), n=15 (whole milk), n=14 (alcohol)
I
InterventionSingle oral dose of 750 mg pharmaceutically pure CBD (Epidiolex/Epidyolex, 100 mg/mL solution) under various food conditions
C
ControlFasted state
O
OutcomeAUC0-∞ increased 3,8-fold (high-fat), 2,7-fold (low-fat), 2,4-fold (whole milk), 1,6-fold (alcohol) vs. fasted; Cmax increased 5,2-fold, 3,8-fold, 3,1-fold and 1,9-fold respectively; no clinically relevant effects on tmax or t½
Confidence in the evidence
Moderate
The third of four GRADE levels, the effect estimate is probably reliable.
Downgraded for
Imprecision
Quality profile
Sample size
★★★★★
Blinding
Open-label
Effect size
Clear benefit
Citations / year
★★★★★
Authors
Share
Abstract
<h4>Objective</h4>The pharmacokinetics (PK) and safety of single oral 750-mg doses of a plant-derived pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex in the USA and Epidyolex in Europe; 100-mg/mL oral solution) were assessed in healthy adults following a high-fat/calorie meal (n = 15), a low-fat/calorie meal (n = 14), whole milk (n = 15), or alcohol (n = 14), relative to the fasted state (n = 29).<h4>Methods</h4>Blood samples were collected until 96 hours postdose in each period and evaluated by liquid chromatography and tandem mass spectrometry. PK parameters (maximum observed plasma concentration [C<sub>max</sub> ], area under the plasma concentration-time curve from time zero to the last observed quantifiable concentration, area under the concentration-time curve from time zero to infinity [AUC<sub>0-∞</sub> ], and time to maximum plasma concentration [t<sub>max</sub> ]) of CBD and its major metabolites were derived using noncompartmental analysis.<h4>Results</h4>CBD exposure increased by 3.8-fold for AUC<sub>0-∞</sub> and 5.2-fold for C<sub>max</sub> when CBD was administered with a high-fat/calorie meal versus fasted. To a lesser extent, a low-fat/calorie meal enhanced CBD exposure versus fasted with a 2.7-fold increase in AUC<sub>0-∞</sub> and a 3.8-fold increase in C<sub>max</sub> . Similarly, when dosed with whole milk, CBD exposure increased versus fasted by 2.4-fold for AUC<sub>0-∞</sub> and 3.1-fold for C<sub>max</sub> . Modest elevations in CBD exposure occurred when it was dosed with alcohol: 1.6-fold for AUC<sub>0-∞</sub> and 1.9-fold for C<sub>max</sub> . No clinically relevant effect of any test condition on CBD t<sub>max</sub> or t<sub>½</sub> versus the fasted state was apparent. The same trend was seen for the CBD metabolites, except that 7-carboxy-cannabidiol t<sub>max</sub> was considerably longer when CBD was administered with alcohol (14 vs 4 hours fasted). Inter- and intrasubject variability in PK parameters was moderate to high during the trial.<h4>Significance</h4>CBD and metabolite exposures were most affected by a high-fat/calorie meal. CBD exposures also increased with a low-fat/calorie meal, whole milk, or alcohol, but to a lesser extent. CBD was tolerated, and there were no severe or serious adverse events during the trial.
The impediment to action advances action.